Orphan designation: lusvertikimab Treatment of acute lymphoblastic leukaemia, 25/07/2023 Positive | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 26 January 2024 - 16:13

Orphan designation: lusvertikimab Treatment of acute lymphoblastic leukaemia, 25/07/2023 Positive

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2802

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters